BBIO vs RARE
BBIO: BridgeBio translates genetic science into medicines for rare genetic diseases through a decentralized portfolio model, with an FDA-approved lead product in transthyretin amyloidosis and multiple late-stage programs approaching commercialization. RARE: Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
Side-by-side fundamentals
| Metric | BBIO | RARE | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $84.12 | $26.89 | |
| Market cap as of 2026-07-30 | $16.5B | $2.6B | |
| PEG as of 2026-07-30 | -3.75 | -1.11 | BBIO lower |
| Net margin as of 2026-07-30 | -124.4% | -91.0% | RARE higher |
| Gross margin as of 2026-07-30 | +95.1% | +83.6% | BBIO higher |
| Operating margin as of 2026-07-30 | -90.5% | -83.8% | RARE higher |
| ROE as of 2026-07-30 | -206.7% | -414.2% | BBIO higher |
| ROA as of 2026-07-30 | -65.8% | -45.7% | RARE higher |
| Debt / equity as of 2026-07-30 | 8.27 | 90.54 | BBIO lower |
| Revenue growth (YoY) as of 2026-07-30 | +355.2% | +13.3% | BBIO higher |
| Revenue CAGR (3y) SEC XBRL | +86.3% | +22.8% | BBIO higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-30 | 0.96 | 0.30 | |
| 1-year return as of 2026-07-27 close | +81.7% | -1.6% | BBIO higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.